Switching anti-TNF-alpha agents: what is the evidence? (Q36960252)

17 August 2017

1 reference

title

Switching anti-TNF-alpha agents: what is the evidence? (English)

1 reference

17 August 2017

0 references

Alan R Erickson

1

1 reference

PubMed ID

17915098

17 August 2017

Ted R Mikuls

series ordinal

2

1 reference

17 August 2017

1 October 2007

1 reference

Current Rheumatology Reports

17 August 2017

1 reference

17 August 2017

9

1 reference

17 August 2017

5

1 reference

17 August 2017

416-420

1 reference

https://scigraph.springernature.com/pub.10.1007/s11926-007-0066-2

17 August 2017

0 references

cites work

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

1 reference

12 December 2020

Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure

1 reference

12 December 2020

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept

1 reference

12 December 2020

Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection

1 reference

12 December 2020

Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial.

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders.

1 reference

12 December 2020

Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease

1 reference

12 December 2020

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period

1 reference

12 December 2020

Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study

1 reference

12 December 2020

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

1 reference

12 December 2020

Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab

1 reference

12 December 2020

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

1 reference

12 December 2020

Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept

1 reference

12 December 2020

Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody

1 reference

12 December 2020

Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital

1 reference

12 December 2020

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

12 December 2020

Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study

1 reference

12 December 2020

Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects

1 reference

12 December 2020

Switching tumor necrosis factor inhibitors: an opinion

1 reference

12 December 2020

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

12 December 2020

10.1007/S11926-007-0066-2

Identifiers

DOI

1 reference

17 August 2017

1 reference

PubMed ID

17915098